Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 12/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | CCNC | P24863 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2953763 | 0.90 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3391053 | 0.89 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3182713 | 0.88 | KCNJ6 (0.57) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3389715 | 0.88 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3185785 | 0.86 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3390236 | 0.86 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3391933 | 0.86 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3174170 | 0.85 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3170749 | 0.85 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3388935 | 0.85 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943243-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7652015-B2 | Suppression cytokines , tumor necrosis factor | ELI LILLY AND COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080269244-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269244-A1 | Kinase Inhibitors | MAP3K1, MAP3K20, MAP3K19 | MAPK14 58/4885MAPK13 60/4885MAPK12 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.